• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Biotech Acquisition Company (Amendment)

    2/13/23 2:11:40 PM ET
    $BIOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOT alert in real time by email
    SC 13G/A 1 sc_13ga_biotechacquisition.htm
     
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     
     

    SCHEDULE 13G/A
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)
     
     

    Biotech Acquisition Company
    (Name of Issuer)
    Class A Ordinary Shares, par value $0.0001 per share
    (Title of Class of Securities)
    G1125A108
    (CUSIP Number)
    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)
     
     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [X]  Rule 13d-1(b)
    [   ]  Rule 13d-1(c)
    [   ]  Rule 13d-1(d) 
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     




    CUSIP No. G1125A108
     
     
      1.  
      NAME OF REPORTING PERSONS
     
      Aristeia Capital, L.L.C.
     
     
      2.  
      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)  ☐        (b)  ☐
     
     
     
      3.  
      SEC USE ONLY

     
     
     
      4.  
      CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware
     
    NUMBER OF
    SHARES
      BENEFICIALLY  
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
      5.  
      SOLE VOTING POWER
     
    1,524,010 (1)
    6.  
      SHARED VOTING POWER
     
      0
    7.  
      SOLE DISPOSITIVE POWER
     
      1,524,010 (1)
    8.  
      SHARED DISPOSITIVE POWER
     
      0
     
      9.  
      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
      1,524,010 (1)
     
     
    10.  
      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
      ☐
     
     
    11.  
      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
      6.63 %
     
     
    12.  
      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
      IA, OO
     

    (1)
     
    Aristeia Capital, L.L.C. is the investment manager of, and has voting and investment control with respect to the securities described herein held by, one or more private investment funds.
     
     
       



    Item 1.
    (a).
    Name of Issuer:
       
    Biotech Acquisition Company (the “Issuer”)
    Item 1.
    (b).
    Address of Issuer’s Principal Executive Offices:
       
    545 West 25th St, 20th Floor
    New York, New York 10001
     
    Item 2.
    (a).
    Name of Person Filing:
    Item 2.
    (b).
    Address of Principal Business Office or, If None, Residence.
    Item 2.
    (c)
    Citizenship.
       
    Aristeia Capital, L.L.C.
    One Greenwich Plaza, 3rd Floor
    Greenwich, CT 06830
    Delaware limited liability company
     
    Item 2.
    (d).
    Title of Class of Securities:
       
    Class A Ordinary Shares, par value $0.0001 per share (“Shares”)
    Item 2.
    (e).
    CUSIP Number:
       
    G1125A108

    Item 3.
    If this statement is filed  pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:
     
    (a)
    ☐
    Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
     
    (b)
    ☐
    Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
     
    (c)
    ☐
    Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
     
    (d)
    ☐
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e)
    ☒
    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
     
    (g)
    ☐
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
     
    (h)
    ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j)
    ☐
    Group, in accordance with  § 240.13d-1(b)(1)(ii)(J).

    Item 4
    Ownership
     
    The following is information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 as of 12/31/2022.
     
    Items 5-9 and 11 of the cover page to this Schedule 13G are incorporated herein by reference.
     
     
    (a)
    Amount beneficially owned:  1,524,010
     
    (b)
    Percent of Class:  6.63 %
     
    (c)
    Number of shares as to which such person has:
       
    (i)
    sole power to vote or direct the vote:  1,524,010
       
    (ii)
    shared power to vote or direct the vote:  0
     
     
    The percentage of Shares reported to be beneficially owned by the Reporting Persons is based on 23,000,000 Shares outstanding as of November 21, 2022, as reported in the Issuer’s Form 10-Q for the quarterly period ending September 30, 2022 filed with the SEC on November 22, 2022.
     
    Item 5.
    Ownership of Five Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [] .

    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
    N/A
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
     
    N/A
    Item 8.
    Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     
     
    N/A
    Item 9.
    Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
     
     
    N/A
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    February 13, 2023
         
       
    ARISTEIA CAPITAL, L.L.C.
           
       
    By:
    /s/ Andrew B. David
         
    Name: Andrew B. David
         
    Title:   Chief Operating Officer


    Get the next $BIOT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Biotech Acquisition Company

      15-12G - Biotech Acquisition Co (0001825413) (Filer)

      2/14/23 4:40:30 PM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Biotech Acquisition Company

      25-NSE - Biotech Acquisition Co (0001825413) (Subject)

      2/2/23 4:55:30 PM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biotech Acquisition Company filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Biotech Acquisition Co (0001825413) (Filer)

      2/1/23 8:00:32 PM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOT
    Leadership Updates

    Live Leadership Updates

    See more
    • Blade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical Development

      Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the appointment of Bassem Elmankabadi, M.D., as senior vice president of clinical development. In this role, Dr. Elmankabadi will oversee strategy and execution of Blade's clinical development programs. "Dr. Elmankabadi has an extensive track record driving drug development from proof-of-concept through launch across multiple therapeutic areas," said Wendye Robbins, M.D., president and CEO of Blade. "I am thrilled to welcome Dr. Elmankabadi to the Blade team as we seek to advance our clinical-stage pipeline t

      11/18/21 8:00:00 AM ET
      $AMGN
      $BIOT
      $FGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BIOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Biotech Acquisition Company (Amendment)

      SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

      2/14/24 9:12:34 AM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Biotech Acquisition Company (Amendment)

      SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

      2/14/23 10:50:25 AM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Biotech Acquisition Company

      SC 13G - Biotech Acquisition Co (0001825413) (Subject)

      2/14/23 10:35:55 AM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biotech Acquisition Company Announces Liquidation

      New York, New York, Feb. 01, 2023 (GLOBE NEWSWIRE) --  Biotech Acquisition Company (the "Company") (NASDAQ:BIOT), announced today that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on January 19, 2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account ("Trust Account") for the extension. As a result, the Company will dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended (the "Charter") and will redeem

      2/1/23 7:50:00 PM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment

      NEW YORK, Jan. 4, 2023 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed extension (the "Extension") of the time period the Company has to complete an initial business combination, as described in the Proxy Statement (as defined below), IREEM LLC, which has entered into an agreement to acquire the current sponsor's interest in the Company (as described in the Proxy Statement), will deposit into the Company's trust account (the "Trust Account") for each additional month the lesser of (i) an aggregate of $457,500 or (ii) $0.055 per share that remains outstanding an

      1/4/23 5:51:00 PM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blade Therapeutics to Participate in "Drug Development in Pulmonary Medicine" Panel Discussion at 2022 BTIG Biotechnology Conference

      Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will participate in the "Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need" panel discussion on Tuesday, August 9, 2022, 1:00 pm (ET), during the 2022 BTIG Biotechnology Conference, August 8 – 9, in New York City. Blade's lead investigational medicine is cudetaxestat, a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial i

      8/1/22 8:00:00 AM ET
      $BIOT
      Biotechnology: Pharmaceutical Preparations
      Health Care